Screener / SEC EDGAR /CIK 0001739104 /10-K filed Feb 24, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Pharmaceuticals

Elanco Animal Health Inc ELAN

Compare with peers Embed
SEC comment letters, last 20 years

2 reviews of ELAN's filings by SEC staff

UPLOAD and CORRESP
Reviews 2 latest letter Mar 12, 2024
Questions asked 5 each answered in the company's own letter
No closing letter 2 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 2 UPLOAD
  2. 2. Questions in them 5 numbered comments
  3. 3. Company replies 3 CORRESP
  4. 4. Reviews closed 0 of 2 closing letter

Elanco Animal Health Inc · Soliciting Materials filed pursuant to Rule 14a-12 by Ancora Holdings Group, LLC et al. · Filed February 29, 2024 · File No. 001-38661

2024-03-12 to 2024-03-12 · 4 questions · 1 letter from the SEC, 0 from the company
No closing letter
RevenueNon-GAAP measuresLiquidity and cashAcquisitions
SEC letter of Mar 12, 2024 ↗ no reply letter on EDGAR
Presentation, page 6
SEC asked (1)
We note your repeated references to your expectations about what the company will claim (pages 6 and 8). It is unclear how you are able to predict what the company will claim or say. Please provide support for your statements or confirm that you will refrain from making similar statements in future filings.
ELAN answered

No reply letter found.

Presentation, page 6
SEC asked (2)
Each statement or assertion of opinion or belief must be clearly characterized as such, and a reasonable factual basis must exist for each such opinion or belief. Support for opinions or beliefs should be self-evident, disclosed in the proxy statement or provided to the staff on a supplemental basis. With a view toward revised disclosure, provide support for your statements: • in each of the six boxes on page 11.
Rest of the question

• that the company overpaid in the Bayer acquisition (page 19). • that Mr. Simmons has failed to execute on revenue growth, growth margin, EBITDA margin, leverage and free cash flow since the company's IPO (page 19). In this respect, we note that later slides refer to estimated 2024 results while the referenced statement presents your view as to historical results. • that the company "continues to disingenuously highlight EBITDA improvement" (page 24). • that "net working capital has become a meaningful drag" (page 25). • that proxy advisory firms have recommended against the election of incumbent directors (page 27).

ELAN answered

No reply letter found.

Presentation, page 6
SEC asked (3)
Avoid issuing statements in your proxy statement that directly or indirectly impugn the character, integrity or personal reputation or make charges of illegal, improper or immoral conduct without factual foundation. Disclose the factual foundation for such assertions or delete the statements. In this regard, note that the factual foundation for such assertions must be reasonable. Refer to Rule 14a-9.
Rest of the question

Please provide us supplementally the factual foundation for your disclosures that "The Board is clearly committed to ignoring the will of shareholders, underscoring its culture of entrenchment." (page 27)

ELAN answered

No reply letter found.

Presentation, page 6
SEC asked (4)
Please provide us supplemental support for the disclosure in the last bullet point on page 28.
ELAN answered

No reply letter found.

Form S-4

2019-02-15 to 2019-06-12 · 1 question · 1 letter from the SEC, 3 from the company
No closing letter
Results discussion (MD&A)
Conditions to Completion of the Exchange Offer, page 85
SEC asked
Disclosure on page 86 indicates that Lilly may terminate the exchange offer if there occurs, or Lilly reasonably expects there may occur, a material adverse change in the stock price of Elanco or the stock price of Lilly.
Rest of the question

Given the condition immediately preceding these two conditions that quantifies a decline of the closing level in the Dow Jones Industrial Average or the Standard & Poor’s 500 Index of 10% from the closing level established on February 7, 2019, please advise what consideration Lilly and Elanco gave to disclosing to holders a similar quantification with respect to the stock price of Lilly and Elanco. In responding to this comment, please consider the fact that the offer already provides for an upper limit on the exchange ratio that appears to be triggered under certain stock price scenarios illustrated on page 74.

ELAN answered
Lilly and Elanco considered that there could be material adverse changes to the stock prices of Lilly and Elanco, respectively, during the pendency of the exchange offer that could impair the benefits sought by Lilly to be achieved by the exchange offer. Lilly further considered that material simultaneous declines to both stock prices might, depending upon the relative magnitude of the changes, result in a situation where the upper limit on the exchange ratio would not be in effect but the benefits sought by Lilly through the exchange offer nonetheless would not be obtained.
Rest of the answer

Lilly and Elanco believe that distilling these possible stock price decline scenarios to a quantitative or mathematical standard or formula is not practicable. Lilly and Elanco also believe that such a quantification would be unusual or possibly unprecedented for exchange offers of this type and could itself have an adverse impact on the exchange offer. To make clearer the situations intended to be covered by these two conditions, however, the Registration Statement has been revised to add to the end of each of these conditions: “which in Lilly’s reasonable judgment would impair the benefits of the exchange offer.”

Read in the reply

Also in this review: company letter, May 24, 2019, company letter, Jun 12, 2019

SEC enforcement releases naming ELAN

Litigation releases and accounting and auditing enforcement releases (AAER) · sec.gov

1

A release is listed only when SEC's list names Elanco Animal Health Inc (or a name it had before) among those the action is against. The page does not say what the release found: open it on sec.gov. A release against a person at the company, or one that names the company under another spelling, is not matched, so this list can be shorter than SEC's.

Letters without questions

Other letters

UPLOAD and CORRESP
3 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 8 letters filed since 2019-02-22. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ELAN/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.